Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365756 | 0.87 | HPGDS (0.55) | HPGDSGABRA5KMT2ADRD2DRD4 | |
| SCHEMBL2070012 | 0.84 | HPGDS (0.73) | HPGDSGABRA5DRD2DRD4HTR7 | |
| SCHEMBL1543837 | 0.80 | GABRA5 (0.50) | HPGDSGABRA5MAP4K4NTRK1HTR7 | |
| SCHEMBL1543835 | 0.80 | GABRA5 (0.50) | HPGDSGABRA5MAP4K4NTRK1HTR7 | |
| SCHEMBL2072621 | 0.80 | HPGDS (0.47) | HPGDSGABRA5KMT2ADRD2DRD4 | |
| SCHEMBL1365844 | 0.79 | MAPK14 (0.43) | HPGDSKMT2ADRD2DRD4MEN1 | |
| SCHEMBL1365957 | 0.79 | L3MBTL1 (0.46) | HPGDSGABRA5KMT2AMEN1HTR7 | |
| SCHEMBL1365697 | 0.77 | MAP4K4 (0.49) | HPGDSGABRA5DRD2DRD4MAP4K4 | |
| SCHEMBL1367288 | 0.76 | PHGDH (0.49) | HPGDSKMT2ADRD4MEN1 | |
| SCHEMBL1364287 | 0.75 | SMYD3 (0.46) | HPGDSKMT2AMEN1CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | HPGDS 984/4885GABRA5 1998/4885KMT2A 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.